Related Experiment Videos
Gemcitabine-related pulmonary toxicity
1Department of Internal Medicine, Division of Oncology, University Hospital, Rämistrasse 100, CH-8091 Zurich, Switzerland.
Swiss Medical Weekly
|March 20, 2002
Summary
Gemcitabine can cause rare but fatal lung toxicity. Early diagnosis and steroid treatment reversed this toxicity in all observed patients, highlighting the need for prompt recognition.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Gemcitabine is a widely used chemotherapy agent.
- Pulmonary toxicity is a rare but serious adverse effect of gemcitabine.
- This condition can be life-threatening if not managed promptly.
Observation:
- This study details 5 cases of gemcitabine-induced pulmonary toxicity.
- Patients presented with varying clinical features of lung injury.
- The key intervention was early identification and cessation of gemcitabine.
Findings:
- Prompt discontinuation of gemcitabine was crucial for recovery.
- Corticosteroid therapy significantly aided in reversing the pulmonary toxicity.
- All 5 patients experienced a reversible course of toxicity with timely intervention.
Implications:
- Early recognition of gemcitabine-related pulmonary toxicity is essential for patient outcomes.
- Clinicians should maintain a high index of suspicion for pulmonary adverse events during gemcitabine therapy.
- This underscores the importance of multidisciplinary management in cancer drug toxicity.